Column Capital Advisors’s AYTU BioPharma AYTU Stock Holding History

Column Capital Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6	Closed	-$1K	–	720
2021 Q1	$1K	Buy	+6	New	+$952	﹤0.01%	649

Other funds holding AYTU

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Column Capital Advisors's AYTU Position: Q2 2021 in Review

Column Capital Advisors sold out of AYTU BioPharma (AYTU) in Q2 2021, closing a stake of 6 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in AYTU in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 50 funds tracked by Wall St. Rank hold AYTU as of Q2 2021.

Column Capital Advisors reported no remaining AYTU BioPharma position as of Q2 2021 after selling out during the quarter.
Column Capital Advisors sold 6 AYTU BioPharma shares in Q2 2021, an estimated $1K.
Column Capital Advisors first reported a position in AYTU BioPharma in Q1 2021 and held it in 1 quarter.
Column Capital Advisors's AYTU BioPharma position peaked at $1K in Q1 2021.
50 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2021.

Based on Column Capital Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.